PY2018921A - Agentes antiproliferativos para el tratamiento de pah - Google Patents

Agentes antiproliferativos para el tratamiento de pah

Info

Publication number
PY2018921A
PY2018921A PY202002018921A PY2018921A PY2018921A PY 2018921 A PY2018921 A PY 2018921A PY 202002018921 A PY202002018921 A PY 202002018921A PY 2018921 A PY2018921 A PY 2018921A PY 2018921 A PY2018921 A PY 2018921A
Authority
PY
Paraguay
Prior art keywords
compounds
salts
compositions
pah
treatment
Prior art date
Application number
PY202002018921A
Other languages
English (en)
Inventor
Douglas Carl Behenna
Samit Kumar Bhattacharya
Kimberly O Cameron
Ping Chen
John M Curto
Kevin Daniel Freeman-Cook
Mehran Jalaie
Robert Steven Kania
Yajing Lian
Sajiv Krishnan Nair
Cynthia Louise Palmer
Martin Youngjin Pettersson
Eugene Yuanjin Rui
Matthew Sammons
Qingyi Yang
Liying Zhang
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PY2018921A publication Critical patent/PY2018921A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La presente invención se refiere a compuestos de la Fórmula I en donde A, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> y R<sup>4</sup> son como se definen en la presente, y las sales de estos aceptables desde el punto de vista farmacéutico; a composiciones farmacéuticas que comprenden tales compuestos y sales; a métodos para usar tales compuestos, sales y composiciones para tratar hipertensión pulmonar y enfermedades relacionadas, tal como hipertensión arterial pulmonar; a métodos de usar tales compuestos, sales y composiciones para tratar el crecimiento anormal, tal como cáncer; y a procesos para elaborar tales compuestos, sales y composiciones.
PY202002018921A 2019-04-19 2020-05-07 Agentes antiproliferativos para el tratamiento de pah PY2018921A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962836340P 2019-04-19 2019-04-19
US202062981620P 2020-02-26 2020-02-26

Publications (1)

Publication Number Publication Date
PY2018921A true PY2018921A (es) 2021-09-24

Family

ID=70465141

Family Applications (1)

Application Number Title Priority Date Filing Date
PY202002018921A PY2018921A (es) 2019-04-19 2020-05-07 Agentes antiproliferativos para el tratamiento de pah

Country Status (16)

Country Link
US (1) US11203594B2 (es)
EP (1) EP3956031A1 (es)
JP (1) JP2022529930A (es)
KR (1) KR20220003565A (es)
CN (1) CN114007697A (es)
AU (1) AU2020260018A1 (es)
BR (1) BR112021020295A2 (es)
CA (1) CA3136880C (es)
IL (1) IL287374A (es)
MX (1) MX2021012491A (es)
PY (1) PY2018921A (es)
SG (1) SG11202111533XA (es)
TW (1) TWI744866B (es)
UY (1) UY38665A (es)
WO (1) WO2020212865A1 (es)
ZA (1) ZA202107695B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023515629A (ja) * 2020-02-28 2023-04-13 フォチョン・バイオサイエンシーズ・リミテッド Ｃｄｋ２／４／６阻害剤としての化合物
AU2022234998B2 (en) * 2021-03-08 2025-04-10 Jinan University Pyridopyrimidine compounds and applications thereof
CN113125602A (zh) * 2021-04-16 2021-07-16 山东铂源药业有限公司 一种哌柏西利中残留溶剂的检测方法
CN114773391A (zh) * 2022-03-24 2022-07-22 联碳新材料技术(杭州)有限公司 一种含氟过渡金属配合物、其制备方法和应用
EP4519267A4 (en) * 2022-05-05 2026-02-25 Beone Medicines I Gmbh HETEROCYCLIC COMPOUNDS, THEIR COMPOSITIONS AND ASSOCIATED PROCESSING METHODS
CN114751884A (zh) * 2022-05-06 2022-07-15 河南应用技术职业学院 一种（3s,4r）-4-氨基氧杂环己-3-醇的合成方法
WO2026026894A1 (zh) * 2024-08-01 2026-02-05 浙江奥翔药业股份有限公司 一种角鲨胺关键中间体的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
DE3438830A1 (de) 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
KR0182801B1 (ko) 1991-04-16 1999-05-01 아만 히데아키 고체 분산체의 제조방법
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
JP3265680B2 (ja) 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
DE19504832A1 (de) 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
ATE364374T1 (de) 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
CA2575804A1 (en) * 2004-08-26 2006-03-02 Boehringer Ingelheim International Gmbh Pteridinones used as plk (polo like kinase) inhibitors
MX369369B (es) * 2014-02-07 2019-11-06 Principia Biopharma Inc Derivados de quinolona como inhibidores del receptor del factor de crecimiento de fibroblastos.
CN109803968A (zh) 2016-08-15 2019-05-24 辉瑞公司 吡啶并嘧啶酮cdk2/4/6抑制剂
CA3040815C (en) 2016-10-20 2021-07-20 Steven Martin Evans Anti-proliferative agents for treating pah

Also Published As

Publication number Publication date
TW202104224A (zh) 2021-02-01
AU2020260018A1 (en) 2021-11-04
CN114007697A (zh) 2022-02-01
BR112021020295A2 (pt) 2021-12-14
KR20220003565A (ko) 2022-01-10
UY38665A (es) 2020-11-30
SG11202111533XA (en) 2021-11-29
IL287374A (en) 2021-12-01
CA3136880A1 (en) 2020-10-22
WO2020212865A1 (en) 2020-10-22
US20200331909A1 (en) 2020-10-22
MX2021012491A (es) 2022-01-24
EP3956031A1 (en) 2022-02-23
ZA202107695B (en) 2023-04-26
JP2022529930A (ja) 2022-06-27
TWI744866B (zh) 2021-11-01
CA3136880C (en) 2023-09-19
US11203594B2 (en) 2021-12-21

Similar Documents

Publication Publication Date Title
PY2018921A (es) Agentes antiproliferativos para el tratamiento de pah
ECSP21091615A (es) Derivados de benzisoxazol sulfonamida
MX2022012306A (es) Inhibidores alostericos de cromenona del fosfoinositido 3-quinasa (pi3k) para el tratamiento de enfermedades.
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
CR20200484A (es) COMPUESTOS DE DIHIDROISOQUINOLINONA SUSTITUIDA (Divisional 2016-0574)
MX2023001876A (es) Derivados de rapamicina.
PY1996328A (es) Compuestos de azalactam como inhibidores de hpk1
MX2021011606A (es) Compuestos dirigidos a prmt5.
CL2024000067A1 (es) Compuestos antivirales
CO2020014677A2 (es) Compuestos tetrahidro-1h-pirazino[2,1-a]isoindolilquinolina para el tratamiento de enfermedades autoinmunes
CO2019000932A2 (es) Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica.
CO2022004698A2 (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
CO2019001181A2 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
MX2020004283A (es) Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.
CL2017002745A1 (es) Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas
UY39181A (es) COMPUESTOS Y COMPOSICIONES PARA INHIBIR LA ACTIVIDAD DE HIF2a Y SUS MÉTODOS DE USO
AR127470A1 (es) Inhibidores de lrrk2
CO2025003099A2 (es) Compuestos para el tratamiento del cáncer
CO2025011377A2 (es) Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno
CO2022006942A2 (es) Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria
ECSP24038829A (es) Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
UY37745A (es) Compuestos bicíclicos 5,6 fusionados y composiciones para el tratamiento de las enfermedades parasitarias
MX2021009584A (es) Nuevos derivados de triterpeno como inhibidores del virus de la inmunodeficiencia humana (vih).
UY39466A (es) Compuestos y composiciones para el tratamiento de la criptosporidiosis
AR131945A1 (es) Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno